Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01272531 · ClinicalTrials.gov registry record
Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)
A clinical trial of Bipolar Affective Disorder, sponsored by University of California, San Diego.
- Completed
- Registry status
- 560
- Enrollment target
- 10
- Study locations
NCT01272531: Completed study of Bipolar Affective Disorder, sponsored by University of California, San Diego.
NCT01272531 is a study of Bipolar Affective Disorder that has completed, run by University of California, San Diego. The registered enrollment target is 560 participants. The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01272531, a study of Bipolar Affective Disorder, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- 560 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a prospective pharmacogenomics study of mood stabilizer response. The goal of this work is to identify genes associated with good response of patients with bipolar disorder to two commonly used mood stabilizing agents, lithium and valproate.
Primary Outcome
Relapse definition: * meets criteria for mania and is considered "markedly ill" or worse; or * meets criteria for major depression with 4 week duration; * meets criteria for a mixed episode and is considered "markedly ill" or worse.
Conditions Studied
Interventions
- DRUG Mood stabilizer treatment
Study Locations (10)
California
- University of California San Diego - San Diego
Illinois
- University of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa - Iowa City
Maryland
- Johns Hopkins Hospital - Baltimore
Michigan
- University of Michigan - Ann Arbor
Ohio
- University Hospitals Case Medical Center - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2011-04 |
| Est. Completion | 2016-04 |
What the finished NCT01272531 record still lists
NCT01272531 is an observational study that tracks outcomes without assigning an intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Bipolar Affective Disorder appearing as the primary indexed condition, and to 1 intervention - of which Mood stabilizer treatment is the first listed.
NCT01272531 lists 10 locations in 10 states (California, Illinois, Indiana).
Frequently Asked Questions
What is clinical trial NCT01272531 about?
NCT01272531 is a clinical study titled "Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)". This is a prospective pharmacogenomics study of mood stabilizer response. The goal of this work is to identify genes associated with good response of patients with bipolar disorder to two commonly used mood stabilizing agents, lithium and valproate.
What is the current status of trial NCT01272531?
This trial is currently completed. The enrollment target is 560 participants. The study started on 2011-04. Estimated completion is 2016-04.
What conditions does trial NCT01272531 study?
This clinical trial studies the following conditions: Bipolar Affective Disorder.
What interventions are being tested in trial NCT01272531?
The interventions under investigation include: Mood stabilizer treatment (DRUG).
Who is sponsoring clinical trial NCT01272531?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01272531 being conducted?
This trial has 10 study locations across California, Illinois, Indiana, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia